707-34-6

Basic information

• Product Name: 1,3,5-TRIBROMOADAMANTANE
• Synonyms: SALOR-INT L496510-1EA;LABOTEST-BB LT00077082;1,3,5-TRIBROMOADAMANTANE
• CAS NO: 707-34-6
• Molecular Formula: C₁₀H₁₃Br₃
• Molecular Weight: 372.92
• Product Categories: Adamantane derivatives
• Mol File: 707-34-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 126-127℃ (hexane )
• Boiling Point: 329.0±22.0 °C(Predicted)
• Appearance: /
• Density: 2.235±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1,3,5-TRIBROMOADAMANTANE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,5-TRIBROMOADAMANTANE(707-34-6)
• EPA Substance Registry System: 1,3,5-TRIBROMOADAMANTANE(707-34-6)

Safety Data

• Hazardous Substances Data: 707-34-6(Hazardous Substances Data)

Usage

Description

1,3,5-Tribromoadamantane is a brominated organic compound with the chemical formula C10H15Br3. It is a white crystalline solid and is known for its unique structure and properties. 1,3,5-TRIBROMOADAMANTANE is an impurity found in Memantine, which is an antiparkinsonian and antispasmodic agent.

Uses

Used in Pharmaceutical Industry:
1,3,5-Tribromoadamantane is used as a brominated impurity in the production of Memantine (M218000) for its antiparkinsonian and antispasmodic properties. Memantine is a medication that is primarily used to treat Parkinson's disease and various spastic conditions by acting on the central nervous system.
As an impurity in Memantine, 1,3,5-Tribromoadamantane may have potential effects on the overall efficacy and safety of the drug. It is essential to monitor and control the levels of this impurity during the manufacturing process to ensure the quality and effectiveness of Memantine as a pharmaceutical product.

InChI:InChI=1S/C10H13Br3/c11-8-1-7-2-9(12,4-8)6-10(13,3-7)5-8/h7H,1-6H2

Upstream product

• 281-23-2 adamantane 
• 2825-83-4 (3aR,4R,7S,7aS)-octahydro-1H-4,7-methanoindene 

Downstream Products

• 7314-86-5 1,3,5,7-tetrabromoadamantane 

Relevant articles and documents

Hollow sphere formation from a three-dimensional structure composed of an adamantane-based cage

An adamantane-based cage with a three-dimensional (3D) framework was synthesized by the copper-mediated acetylene coupling reaction, in which two 1,3,5-triethynyladamantane units were linked by phenyldiacetylenic bridges possessing ester groups. X-ray cry

A process for the preparation of adamantane triols

The invention provides a preparation method for adamantanetriol. The method is characterized by consisting of two phases: phase one, reacting adamantane with bromine to generate 1, 3, 5-tribromoadamantane; phage 2, under the action of silver sulfate and concentrated sulfuric acid, letting 1, 3, 5-tribromoadamantane generate adamantanetriol. According to the synthesis method provided by the invention, by selecting the reaction conditions of each step, like reaction temperature, reaction ratio, reaction time, reaction feedstock and the like, the problems of difficult purification, low reaction yield, low product purity, inapplicability to large-scale industrial production and the like in existing technical disclosures can be overcome.

Synthesis of Well-Defined Tower-Shaped 1,3,5-Trisubstituted Adamantanes Incorporating a Macrocyclic Trilactam Ring System

We describe the synthesis of two novel well-defined tower-shaped 1,3,5-trisubstituted adamantanes 30 and 33 that incorporate a macrocyclic trilactam ring system. Each nanoscale molecule has a broad tripodal base consisting of three identical sulfur-contai